Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. (RLAY) on November 4, 2025, with the earliest event reported on that date. The filing primarily addresses corporate governance changes and references the announcement of financial results for the quarter ended September 30, 2025, which was issued via press release on November 6, 2025.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not detailed in the body of this 8-K.
Material Changes
- Board Expansion: The Board of Directors increased its size from seven to nine members.
- New Appointments: Lonnel Coats and Habib Dable were appointed as independent directors effective November 4, 2025.
- Committee Assignments: Mr. Coats joined the Audit Committee, and Mr. Dable joined the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Compensation
The filing does not contain specific forward-looking guidance or management commentary on operational outlook beyond the reference to the press release. Regarding compensation for the new directors:
- Both directors received an initial option to purchase up to 207,931 shares of common stock each.
- The exercise price is $6.86 per share, based on the closing price on November 4, 2025.
- Options vest in equal monthly installments over 36 months.
- Directors will also receive cash compensation and equity awards per the company's non-employee director policy.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for the actual Q3 2025 financial results, including cash burn and runway.
- Verify the professional backgrounds of Lonnel Coats and Habib Dable to assess their specific expertise relative to the company's pipeline.
- Confirm the total number of outstanding shares and the impact of the new director options on dilution.
- Check the company's cash position and liquidity status as of September 30, 2025, which is not detailed in this filing.